CareDx, a company specializing in transplant diagnostics, has reported its preliminary financial results for the third quarter of 2024. The company indicated a revenue increase of 23 percent compared to the previous year. However, shares of CareDx, trading under the ticker $CDNA, experienced an 8.7 percent decline in pre-market trading following the announcement. In a related development, Cryo-Cell, a leader in cord blood banking, also released its fiscal third quarter 2024 financial results on the same day.